{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:54:13Z","timestamp":1781830453958,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Specialized Discipline","award":["2015-2"],"award-info":[{"award-number":["2015-2"]}]},{"name":"the Key Research and Development Program of Guangxi","award":["AB23026079"],"award-info":[{"award-number":["AB23026079"]}]},{"name":"the Guangxi Natural Science Foundation","award":["2021GXNSFAA196008"],"award-info":[{"award-number":["2021GXNSFAA196008"]}]},{"name":"the Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation","award":["2024GXNSFBA010303"],"award-info":[{"award-number":["2024GXNSFBA010303"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81973533"],"award-info":[{"award-number":["81973533"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04382-8","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:43:48Z","timestamp":1777700628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is surgery necessary for mismatch repair-deficient\/microsatellite instability-high colorectal cancer patients with a clinical complete response after neoadjuvant immunotherapy? A retrospective cohort study with literature context"],"prefix":"10.1186","volume":"24","author":[{"given":"Hongqun","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"4382_CR1","first-page":"233","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233\u201354.","journal-title":"CA Cancer J Clin"},{"key":"4382_CR2","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s12672-025-03791-7","volume":"16","author":"J Wu","year":"2025","unstructured":"Wu J, Zhang H, Luan Z, Chen J, Zhao Z, Zhao Y, Li C, Zhang W, Chen Y, Zhang J, et al. Changing patterns of colorectal cancer in China between 2000 and 2016 based on tertiary hospital data. Discov Oncol. 2025;16:2019.","journal-title":"Discov Oncol"},{"key":"4382_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.ccell.2025.08.010","volume":"43","author":"G Randon","year":"2025","unstructured":"Randon G, Montroni I, Pietrantonio F. Bringing immunotherapy to clinical practice in dMMR\/MSI-high colon cancer. Cancer Cell. 2025;43:1789\u201391.","journal-title":"Cancer Cell"},{"key":"4382_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.dld.2025.08.001","volume":"57","author":"L Sorrentino","year":"2025","unstructured":"Sorrentino L, Nasca V, Daveri E, Lonardi S, Bergamo F, Intini R, Scardino A, Montroni I, Pietrantonio F. MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenteration. Dig Liver Dis. 2025;57:2006\u201310.","journal-title":"Dig Liver Dis"},{"key":"4382_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini M, Manca P, Nasca V, Sciortino C, Ghelardi F, Seligmann JF, Taieb J, Pietrantonio F. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Rev Clin Oncol. 2025;22:385\u2013407.","journal-title":"Nat Rev Clin Oncol"},{"key":"4382_CR6","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang X, Zhong X, Huang L, Jiang W, Zhang C, Liu L, You R, Li Y, Yi X et al. Immunophenotype-guided interpretable radiomics model for predicting neoadjuvant anti-PD-1 response in stage III-IV d-MMR\/MSI-H colorectal cancer. J Immunother Cancer. 2025;13(8):e011569. https:\/\/doi.org\/10.1136\/jitc-2025-011569.","DOI":"10.1136\/jitc-2025-011569"},{"key":"4382_CR7","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1245\/s10434-025-16989-4","volume":"32","author":"SY Mi","year":"2025","unstructured":"Mi SY, Liao YJ, Kang D, Tang X, Chen G, Pan ZZ, Zhan J, Zhang RX. Decreasing Use of CT in Favor of Colonoscopy: A Retrospective Analysis of Post-Operative Imaging in Nonmetastatic dMMR\/MSI-H Sporadic Colorectal Cancer. Ann Surg Oncol. 2025;32:3814\u201327.","journal-title":"Ann Surg Oncol"},{"key":"4382_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00262-024-03926-9","volume":"74","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Liu Y, Huang H, Zhao T, Zhao Z, Gao Y. Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H\/dMMR colorectal cancer. Cancer Immunol Immunother. 2025;74:78.","journal-title":"Cancer Immunol Immunother"},{"key":"4382_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","volume":"36","author":"T Andr\u00e9","year":"2025","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Ann Oncol. 2025;36:277\u201384.","journal-title":"Ann Oncol"},{"key":"4382_CR10","doi-asserted-by":"publisher","unstructured":"Overman MJ, Gelsomino F, Aglietta M, Wong M, Limon Miron ML, Leonard G, Garc\u00eda-Alfonso P, Hill AG, Cubillo Gracian A, Van Cutsem E et al. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Immunother Cancer. 2024;12(5):e008689. https:\/\/doi.org\/10.1136\/jitc-2023-008689.","DOI":"10.1136\/jitc-2023-008689"},{"key":"4382_CR11","doi-asserted-by":"publisher","first-page":"102296","DOI":"10.1016\/j.xcrm.2025.102296","volume":"6","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang X, Zhang X, Leng J, Cui M, Zhang J, Wang Q, Sun Y, Xu T, Chen M, et al. Toripalimab, bevacizumab, and irinotecan in dMMR\/MSI locally advanced colorectal cancer: First-stage results from a phase 1b\/2 trial. Cell Rep Med. 2025;6:102296.","journal-title":"Cell Rep Med"},{"key":"4382_CR12","first-page":"325","volume":"24","author":"A Cercek","year":"2025","unstructured":"Cercek A, Bachet JB, Capdevila J, Starling N, Chen E, Salvatore L, Bando H, O\u2019Donnell S, Harfst L, Szijgyarto Z, Heinemann V. A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II\/III dMMR\/MSI-H Locally Advanced Rectal Cancer (AZUR-1). Clin Colorectal Cancer. 2025;24:325\u201330.","journal-title":"Clin Colorectal Cancer"},{"key":"4382_CR13","doi-asserted-by":"publisher","first-page":"114336","DOI":"10.1016\/j.ejca.2024.114336","volume":"212","author":"O Margalit","year":"2024","unstructured":"Margalit O, Stemmer A, Chapin WJ, Shacham-Shmueli E, Kopetz S, Andre T, Overman MJ, Pietrantonio F, Boursi B. Duration of immunotherapy in dMMR\/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024;212:114336.","journal-title":"Eur J Cancer"},{"key":"4382_CR14","doi-asserted-by":"publisher","first-page":"112231","DOI":"10.1016\/j.jtbi.2025.112231","volume":"613","author":"G Hawi","year":"2025","unstructured":"Hawi G, Kim PS, Lee PP. Optimisation of neoadjuvant pembrolizumab therapy for locally advanced MSI-H\/dMMR colorectal cancer using data-driven delay integro-differential equations. J Theor Biol. 2025;613:112231.","journal-title":"J Theor Biol"},{"key":"4382_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13696998.2022.2043634","volume":"25","author":"R Aguiar-Ib\u00e1\u00f1ez","year":"2022","unstructured":"Aguiar-Ib\u00e1\u00f1ez R, Hardern C, van Hees F, Lee D, Patel A, Chhabra N, Baluni G, Amonkar M, Lai Y, Xu R, et al. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H\/dMMR colorectal cancer in the United States. J Med Econ. 2022;25:469\u201380.","journal-title":"J Med Econ"},{"key":"4382_CR16","doi-asserted-by":"publisher","first-page":"9502","DOI":"10.1245\/s10434-025-18058-2","volume":"32","author":"M Boubaddi","year":"2025","unstructured":"Boubaddi M, Pluchon A, Marichez A, Amintas S, Smith D, Celerier B, Vendrely V, Fernandez B. Local Regrowth After a Watch-and-Wait Strategy for Middle and Low Rectal Cancer: Is Organ Preservation Still Feasible? Ann Surg Oncol. 2025;32:9502\u20139.","journal-title":"Ann Surg Oncol"},{"key":"4382_CR17","doi-asserted-by":"publisher","unstructured":"Jimenez-Rodriguez RM, Aguilar-Del-Castillo F, Quezada-Diaz F, Garc\u00eda-Aguilar J. Organ preservation in rectal cancer: Clinical basis of the watch-and-wait strategy. Cir Esp (Engl Ed). 2026;104(1):800248. https:\/\/doi.org\/10.1016\/j.cireng.2025.800248.","DOI":"10.1016\/j.cireng.2025.800248"},{"key":"4382_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13014-025-02732-6","volume":"20","author":"LY Xu","year":"2025","unstructured":"Xu LY, Jin X, Zhang H, Wu X, Xuan Y, Deng Y, Wang JW, Zhang ZY, Xia F, Zhang Z. Long-term anorectal function in rectal cancer patients managed by a watch-and-wait strategy after total neoadjuvant treatment: a cross-sectional study. Radiat Oncol. 2025;20:154.","journal-title":"Radiat Oncol"},{"key":"4382_CR19","doi-asserted-by":"publisher","first-page":"1182299","DOI":"10.3389\/fimmu.2023.1182299","volume":"14","author":"R Yang","year":"2023","unstructured":"Yang R, Wu T, Yu J, Cai X, Li G, Li X, Huang W, Zhang Y, Wang Y, Yang X, et al. Locally advanced rectal cancer with dMMR\/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study. Front Immunol. 2023;14:1182299.","journal-title":"Front Immunol"},{"key":"4382_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s43441-024-00734-2","volume":"59","author":"RM Califf","year":"2025","unstructured":"Califf RM, Meeker-O\u2019Connell A, Targum S, Marston H. Recent Updates to the Declaration of Helsinki: A View from the U.S. Food and Drug Administration. Ther Innov Regul Sci. 2025;59:929\u201331.","journal-title":"Ther Innov Regul Sci"},{"key":"4382_CR21","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386:2363\u201376.","journal-title":"N Engl J Med"},{"key":"4382_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","volume":"8","author":"G Chen","year":"2023","unstructured":"Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8:422\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4382_CR23","doi-asserted-by":"publisher","first-page":"e70203","DOI":"10.1002\/cncr.70203","volume":"131","author":"J Fang","year":"2025","unstructured":"Fang J, Zheng Z, Chen T, Liu J, Huang J, Zhou D, Huang L, Yang X, Wei H. Efficacy and safety of PD-L1 blockade envafolimab as neoadjuvant treatment in mismatch repair-deficient, locally advanced colorectal cancer: An open-label, single-arm study. Cancer. 2025;131:e70203.","journal-title":"Cancer"},{"key":"4382_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11523-024-01064-x","volume":"19","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang W, Du J, Hu J, Hu R, Zeng Z, Jin-Si-Han EE, Lian S, Wang H, Li Y, et al. Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR\/MSI-H Locally Advanced Colon Cancer. Target Oncol. 2024;19:601\u201310.","journal-title":"Target Oncol"},{"key":"4382_CR25","doi-asserted-by":"publisher","first-page":"111166","DOI":"10.1016\/j.ejso.2025.111166","volume":"52","author":"MA O\u2019Neill","year":"2026","unstructured":"O\u2019Neill MA, Harrold EC, Gillham C, Ryan C, Mehigan BJ, Muldoon C, Martin P, Clancy C, Kavanagh DO, Gallagher DJ, et al. Immunotherapy for downstaging of locally advanced mismatch repair deficient colorectal cancer: A prospective institutional case series. Eur J Surg Oncol. 2026;52:111166.","journal-title":"Eur J Surg Oncol"},{"key":"4382_CR26","doi-asserted-by":"publisher","unstructured":"Yu JH, Liao LE, Xiao BY, Zhang X, Wu AW, Cheng Y, Tang JH, Jiang W, Kong LH, Han K et al. Long-Term Outcomes of dMMR\/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment. J Natl Compr Canc Netw. 2024;22(3):e237096. https:\/\/doi.org\/10.6004\/jnccn.2023.7096.","DOI":"10.6004\/jnccn.2023.7096"},{"key":"4382_CR27","doi-asserted-by":"publisher","first-page":"913483","DOI":"10.3389\/fimmu.2022.913483","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yang R, Wu T, Cai X, Li G, Yu K, Li Y, Ding R, Dong C, Li J, et al. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR\/MSI\u2043H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study. Front Immunol. 2022;13:913483.","journal-title":"Front Immunol"},{"key":"4382_CR28","doi-asserted-by":"publisher","first-page":"114020","DOI":"10.1016\/j.ejca.2024.114020","volume":"202","author":"R Barbe","year":"2024","unstructured":"Barbe R, Belkouchi Y, Menu Y, Cohen R, David C, Kind M, Harguem S, Dawi L, Hadchiti J, Selhane F, et al. Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients. Eur J Cancer. 2024;202:114020.","journal-title":"Eur J Cancer"},{"key":"4382_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJM Williams","year":"2024","unstructured":"Williams CJM, Peddle AM, Kasi PM, Seligmann JF, Roxburgh CS, Middleton GW, Tejpar S. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024;21:839\u201351.","journal-title":"Nat Rev Clin Oncol"},{"key":"4382_CR30","doi-asserted-by":"publisher","unstructured":"Lefevre JH, Dubreuil O, Colle R, Tougeron D, Vienot A, Dupr\u00e9 A, Toullec C, Smith D, Guimbaud R, Chibaudel B et al. Neoadjuvant pembrolizumab with a watch\u2013and\u2013wait strategy for localized MSI\/dMMR colon cancer: Study protocol for a randomized GERCOR 109 - PRODIGE 84 phase II trial (PREMICES). Dig Liver Dis. 2025. 2026;58(1):51\u201355. https:\/\/doi.org\/10.1016\/j.dld.2025.11.003.","DOI":"10.1016\/j.dld.2025.11.003"},{"key":"4382_CR31","doi-asserted-by":"publisher","first-page":"1466497","DOI":"10.3389\/fimmu.2024.1466497","volume":"15","author":"Z Deng","year":"2024","unstructured":"Deng Z, Luo Y, Chen X, Pan T, Rui Y, Hu H, Yan J, Zhang K, Luo C, Song B. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR\/MSI-H locally advanced colorectal cancer. Front Immunol. 2024;15:1466497.","journal-title":"Front Immunol"},{"key":"4382_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00262-024-03764-9","volume":"73","author":"Z Wang","year":"2024","unstructured":"Wang Z, Cheng S, Yao Y, Liu S, Liu Z, Liu N, Jin Y, Zhang Y, Yin F, Han G, et al. Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR\/MSI-H colorectal and gastric cancers. Cancer Immunol Immunother. 2024;73:182.","journal-title":"Cancer Immunol Immunother"},{"key":"4382_CR33","doi-asserted-by":"publisher","first-page":"114128","DOI":"10.1016\/j.ejca.2024.114128","volume":"206","author":"S Ziane Bouziane","year":"2024","unstructured":"Ziane Bouziane S, Mans L, Bucalau AM, Demetter P, Pezzullo M, Andre C, Loi P, Navez J, Marcelis L, Puleo F, et al. Neoadjuvant immunotherapy in microsatellite instability-high (MSI-H) duodenal adenocarcinoma leads to pathological complete response and paves the way for new strategies. Eur J Cancer. 2024;206:114128.","journal-title":"Eur J Cancer"},{"key":"4382_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/SLA.0000000000002761","volume":"268","author":"M Dattani","year":"2018","unstructured":"Dattani M, Heald RJ, Goussous G, Broadhurst J, S\u00e3o Juli\u00e3o GP, Habr-Gama A, Perez RO, Moran BJ. Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. Ann Surg. 2018;268:955\u201367.","journal-title":"Ann Surg"},{"key":"4382_CR35","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","volume":"391","author":"MJM van der Valk","year":"2018","unstructured":"van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537\u201345.","journal-title":"Lancet"},{"key":"4382_CR36","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","volume":"29","author":"M Maas","year":"2011","unstructured":"Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633\u201340.","journal-title":"J Clin Oncol"},{"key":"4382_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1463-1318.2011.02752.x","volume":"14","author":"RS Dalton","year":"2012","unstructured":"Dalton RS, Velineni R, Osborne ME, Thomas R, Harries S, Gee AS, Daniels IR. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Colorectal Dis. 2012;14:567\u201371.","journal-title":"Colorectal Dis"},{"key":"4382_CR38","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.3748\/wjg.v26.i29.4218","volume":"26","author":"F L\u00f3pez-Campos","year":"2020","unstructured":"L\u00f3pez-Campos F, Mart\u00edn-Mart\u00edn M, Fornell-P\u00e9rez R, Garc\u00eda-P\u00e9rez JC, Die-Trill J, Fuentes-Mateos R, L\u00f3pez-Dur\u00e1n S, Dom\u00ednguez-Rull\u00e1n J, Ferreiro R, Riquelme-Oliveira A, et al. Watch and wait approach in rectal cancer: Current controversies and future directions. World J Gastroenterol. 2020;26:4218\u201339.","journal-title":"World J Gastroenterol"},{"key":"4382_CR39","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, Verheij FS, Omer DM, Lee M, Dunne RF, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40:2546\u201356.","journal-title":"J Clin Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04382-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04382-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:31:06Z","timestamp":1781829066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04382-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4382"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04382-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Guangxi Medical University Cancer Hospital (Approval Number: KY2026608; Date of Approval: February 1, 2026).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The requirement for written informed consent for participation in this study was waived by the Institutional Review Board due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"260"}}